HUM
Humana Inc
$
266.680
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
267.420
Open
256.760
VWAP
265.00
Vol
1.68M
Mkt Cap
32.07B
Low
255.6389
Amount
444.78M
EV/EBITDA(TTM)
8.87
Total Shares
120.50M
EV
39.41B
EV/OCF(TTM)
13.44
P/S(TTM)
0.25
Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
31.87B
+8.4%
2.858
-31.29%
31.70B
+8.53%
-3.724
+72.42%
33.24B
+3.51%
10.306
-11%
Estimates Revision
The market is revising Upward the revenue expectations for Humana Inc. (HUM) for FY2025, with the revenue forecasts being adjusted by 0.12% over the past three months. During the same period, the stock price has changed by 6.87%.
Revenue Estimates for FY2025
Revise Upward
+0.12%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+0.17%
In Past 3 Month
Stock Price
Go Up
+6.87%
In Past 3 Month
16 Analyst Rating
8.46% Upside
Wall Street analysts forecast HUM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HUM is 289.25 USD with a low forecast of 244.00 USD and a high forecast of 348.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
9 Hold
0 Sell
Moderate Buy
8.46% Upside
Current: 266.680
Low
244.00
Averages
289.25
High
348.00
8.46% Upside
Current: 266.680
Low
244.00
Averages
289.25
High
348.00
Baird
Neutral
downgrade
$300 -> $297
2025-07-25
Reason
Baird
Price Target
$300 -> $297
2025-07-25
downgrade
Neutral
Reason
Baird lowered the firm's price target on Humana to $297 from $300 and keeps a Neutral rating on the shares as part of an update on the managed care and healthcare facilities group. The firm is increasingly cautious on Medicaid and the healthcare exchange.
Morgan Stanley
Erin Wright
Equal Weight
maintain
$290
2025-07-18
Reason
Morgan Stanley
Erin Wright
Price Target
$290
2025-07-18
maintain
Equal Weight
Reason
Morgan Stanley analyst Erin Wright reiterated an Equal Weight rating and $290 price target on Humana after a court granted the Centers for Medicare and Medicaid Services' motion to dismiss the case the company brought against it and defined all other pending motions as moot. While the firm awaits a decision on whether Humana will appeal or not, it said it is important to note that Humana's earnings bridge to 2028 already assumed Medicare Advantage Stars lawsuit loss in addition to continued Stars challenges in 2027 before returning to top quartile Stars performance in 2028. The firm added that Humana told it that it has exhausted the administrative appeals process with CMS and is exploring all available options including an appeal, a re-filing of the case, and other options.
Truist
David MacDonald
Hold
downgrade
$280 -> $260
2025-07-16
Reason
Truist
David MacDonald
Price Target
$280 -> $260
2025-07-16
downgrade
Hold
Reason
Truist analyst David MacDonald lowered the firm's price target on Humana to $260 from $280 and keeps a Hold rating on the shares as part of a broader research note previewing Q2 results for Healthcare Services. The quarter should reflect an ongoing mixed, sector-dependent backdrop across the firm's coverage universe with a focus on selectivity and utilization-leveraged names best positioned, and Managed Care continuing to face challenges, the analyst tells investors in a research note. Truist adds that it remains bullish on core demand drivers for the industry however and also believes that the Reconciliation Bill has provided increased clarity around regulatory framework.
Truist
David MacDonald
Hold
downgrade
$305 -> $280
2025-06-18
Reason
Truist
David MacDonald
Price Target
$305 -> $280
2025-06-18
downgrade
Hold
Reason
Truist analyst David MacDonald lowered the firm's price target on Humana to $280 from $305 and keeps a Hold rating on the shares. The company's Investor Day presentation provided a solid update on the ongoing attractiveness of the Medicare Advantage market as well as its strong margin expansion opportunity as the Medicaid book further matures, the analyst tells investors in a research note. Truist adds that it sees meaningful avenues for growth at Centerwell and a growth bridge to 2028, though its reduced price target reflects a lower assumed multiple.
BofA
Neutral
downgrade
$320 -> $260
2025-06-18
Reason
BofA
Price Target
$320 -> $260
2025-06-18
downgrade
Neutral
Reason
BofA lowered the firm's price target on Humana to $260 from $320 and keeps a Neutral rating on the shares, stating that the company's new three-year plan targets 2028 EPS implied at $36-$43, which is "roughly in line" with the prior three-year target of $37 for 2025 provided in 2022. The target relies on $4B in cost cutting and margin improvement, which "seems aggressive" given the lower revenue base, but Humana assumes it does not win back the Medicare Advantage Stars it has lost, so this could represent upside if the company does, the analyst tells investors following the company's investor day meeting.
Barclays
Andrew Mok
Equal Weight
downgrade
$273 -> $268
2025-06-12
Reason
Barclays
Andrew Mok
Price Target
$273 -> $268
2025-06-12
downgrade
Equal Weight
Reason
Barclays analyst Andrew Mok lowered the firm's price target on Humana to $268 from $273 and keeps an Equal Weight rating on the shares as part of an investor day preview. The firm expects the company to outline embedded earnings and the path to 3% Medicare Advantage margins, but does not anticipate any formal earnings targets or 2026 guidance.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Humana Inc (HUM.N) is 17.23, compared to its 5-year average forward P/E of 19.24. For a more detailed relative valuation and DCF analysis to assess Humana Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
19.24
Current PE
17.23
Overvalued PE
22.44
Undervalued PE
16.04
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Fair
5Y Average EV/EBITDA
12.33
Current EV/EBITDA
10.45
Overvalued EV/EBITDA
14.34
Undervalued EV/EBITDA
10.33
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
0.52
Current PS
0.24
Overvalued PS
0.67
Undervalued PS
0.37
Financials
Annual
Quarterly
FY2025Q2
YoY :
+9.64%
32.39B
Total Revenue
FY2025Q2
YoY :
-6.78%
1.13B
Operating Profit
FY2025Q2
YoY :
-19.14%
562.00M
Net Income after Tax
FY2025Q2
YoY :
-19.89%
4.51
EPS - Diluted
FY2025Q2
YoY :
+5.28%
1.16B
Free Cash Flow
FY2025Q2
YoY :
-143.90%
1.98
FCF Margin - %
FY2025Q2
YoY :
-26.96%
1.68
Net Margin - %
FY2025Q2
YoY :
-7.18%
6.85
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
948.9K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
1.5M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
485.3K
Volume
6
6-9
Months
246.3K
Volume
10
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
3
327.6K
Volume
Months
6-9
9
3.1M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
258.0K
USD
3
3-6
Months
48.0K
USD
6
6-9
Months
75.0K
USD
1
0-12
Months
91.0K
USD
3
Bought
0-3
2
183.0K
USD
Months
3-6
4
315.0K
USD
Months
6-9
5
231.5K
USD
Months
0-12
1
8.0K
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
948.9K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
1.5M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
HUM News & Events
Events Timeline
2025-08-08 (ET)
2025-08-08
09:31:57
Judges reject 2 cases challenging Medicare negotiation, The Hill reports
2025-07-31 (ET)
2025-07-31
09:49:37
Exact Sciences expands colorectal cancer screening partnership with Humana
2025-07-30 (ET)
2025-07-30
09:55:01
Early notable gainers among liquid option names on July 30th
Sign Up For More Events
Sign Up For More Events
News
4.5
08-08Barron'sThe Stock Market Gains Despite Noisy Week. Call It Complacency—or the Right Thing to Do.
6.5
08-06Barron'sHealthcare Stocks Have Been Beaten Up. The Case for Buying Now.
4.5
08-05NASDAQ.COMStocks Settle Lower as US Service Sector Activity Weakens
Sign Up For More News
People Also Watch
TTWO
Take-Two Interactive Software Inc
217.370
USD
-4.03%
MTB
M&T Bank Corp
187.170
USD
+1.87%
LEN
Lennar Corp
120.850
USD
+1.12%
TPL
Texas Pacific Land Corp
862.100
USD
-0.62%
SLF
Sun Life Financial Inc
56.540
USD
-8.05%
EFX
Equifax Inc
239.810
USD
-0.87%
DXCM
Dexcom Inc
78.860
USD
+3.22%
ED
Consolidated Edison Inc
104.480
USD
-0.50%
MLM
Martin Marietta Materials Inc
610.920
USD
+1.77%
GIS
General Mills Inc
49.830
USD
-0.64%
FAQ
What is Humana Inc (HUM) stock price today?
The current price of HUM is 266.68 USD — it has increased 4.11 % in the last trading day.
What is Humana Inc (HUM)'s business?
What is the price predicton of HUM Stock?
What is Humana Inc (HUM)'s revenue for the last quarter?
What is Humana Inc (HUM)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Humana Inc (HUM)'s fundamentals?
How many employees does Humana Inc (HUM). have?
